In patients with dyslipidemia and type 2 diabetes, 0.1 mg/day pemafibrate decreased the levels of TG and RLP-C and increased the levels of Apo involved in TG and HDL-C metabolism, thereby increasing HDL-C levels. This evidence concerns the gene AOPEP and type 2 diabetes mellitus.